Navigation Links
Genetic Testing Market Outlook to 2017

London (PRWEB) October 02, 2013

A recent report, “Genetic Testing Market Outlook to 2017”, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in around a 140-page report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2012-2017.

Our report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications.

The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report.

Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth.

The report also profiles the twelve most active genetic testing market players worldwide: Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Life Technologies, Genomic Health, Sequenom, Transgenomic, Dako, Gen-Probe, Quest Diagnostics, Genoptix and Clarient. For the purpose of effective competitive analysis of the market, these companies have been analyzed in five major areas namely: business overview, product offerings; financial performance for the last three years, strategic analysis and recent developments.

1. Analyst View
2. Research Methodology
3. Introduction to Genetic Testing
4. Global Genetic Testing Market Overview
4.1 Market Outlook
4.2 Genetic Testing Laboratories - Unmet Need Analysis
4.3 DTC Genetic Testing
5. Disease-Wise Analysis
5.1 Alzheimer's Disease
5.2 Cystic Fibrosis
5.3 Cancer
6. Country-Level Analysis
6.1 US
6.1.1 Market Overview
6.1.2 Recent Developments
6.2 Europe
6.2.1 Market Overview
6.2.2 Recent Developments
6.3 Asia
6.3.1 Market Overview
6.3.2 Recent Developments
7. Emerging Sectors
7.1 Next-Generation Sequencing
7.2 Non-Invasive Prenatal diagnostics (NIPD)
7.3 Whole Genome Sequencing (WGS) for Cancer
7.4 Personalized medicine
8. Competitive Assessment
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Product Offering
8.1.3 Key Financials
8.1.4 Recent Developments
8.1.5 Strengths & Weaknesses
8.2 Roche Diagnostics
8.2.1 Company Overview
8.2.2 Product Offering
8.2.3 Key Financials
8.2.4 Recent Developments
8.2.5 Strengths & Weaknesses
8.3 Myriad Genetics
8.3.1 Company Overview
8.3.2 Product Offering
8.3.3 Key Financials
8.3.4 Recent Developments
8.3.5 Strengths & Weaknesses
8.4 Life Technologies Corporation
8.4.1 Company Overview
8.4.2 Product Offering
8.4.3 Key Financials
8.4.4 Recent Developments
8.4.5 Strengths & Weaknesses
8.5 Genomic Health
8.5.1 Company Overview
8.5.2 Product Offering
8.5.3 Key Financials
8.5.4 Recent Developments
8.5.5 Strengths & Weaknesses
8.6 Sequenom
8.6.1 Company Overview
8.6.2 Product Offering
8.6.3 Key Financials
8.6.4 Recent Developments
8.6.5 Strengths & Weaknesses
8.7 Transgenomic
8.7.1 Company Overview
8.7.2 Product Offering
8.7.3 Key Financials
8.7.4 Recent Developments
8.7.5 Strengths & Weaknesses
8.8 Dako (Agilent Technologies)
8.8.1 Company Overview
8.8.2 Product Offering
8.8.3 Key Financials
8.8.4 Recent Development
8.8.5 Strengths & Weaknesses
8.9 Gen-Probe (Hologic)
8.9.1 Company Overview
8.9.2 Product Offering
8.9.3 Key Financials
8.9.4 Key Activities
8.9.5 Strengths & Weaknesses
8.10 Quest Diagnostics
8.10.1 Company Overview
8.10.2 Products Offerings
8.10.3 Key Financials
8.10.4 Recent Developments
8.10.5 Strengths and Weaknesses
8.11 Genoptix (Novartis)
8.11.1 Company Overview
8.11.2 Product Offerings
8.11.3 Key Financials
8.11.4 Recent Developments
8.11.5 Strengths and Weaknesses
8.12 Clarient (GE Healthcare)
8.12.1 Company Overview
8.12.2 Product Offerings
8.12.3 Key Financials
8.12.4 Recent Developments
8.12.5 Strengths and Weaknesses

List of Figures:

Figure 4-1: Genetic Testing Market (Billion US$), 2012-2017
Figure 4-2: Genetic Testing Market by Geography (%), 2012
Figure 4-3: Number of Companies in Biochemical DTC Genetic Testing Segment (2007-2010)
Figure 4-4: Number of DTC Genetic Testing Companies by Country
Figure 6-1: Number of Laboratories and Diseases for Genetic Testing (1993-2012)
Figure 6-2: US - Number of Genetic Tests (2008 & 2012)
Figure 6-3: US - Genetic Testing Market (Billion US$), 2012-2017
Figure 6-4: Europe - Genetic Testing Market (Billion US$), 2012-2017
Figure 7-1: Global - Next Generation Sequencing Market (Billion US$), 2012-2017
Figure 7-2: Global - NGS Application by Sector (%)
Figure 7-3: Global - Next Generation Sequencing Market by Player (%), 2012
Figure 7-4: US - Non-Invasive Prenatal Diagnostics Market (Million US$), 2012-2016
Figure 7-5: US - Tapped and Untapped Personalized Cancer WGS Market (%), 2013
Figure 7-6: US - Personalized Cancer WGS Market (Million US$), 2012-2017
Figure 8-1: Abbott Laboratories - Revenue Breakup by Geography (%), 2012
Figure 8-2: Abbott Laboratories - Revenue Breakup by Diagnostics Division (%), 2012
Figure 8-3: Roche Holding - Diagnostic Division Revenue by Geography (%), 2012
Figure 8-4: Roche Holding - Revenue Breakup by Diagnostics Division (%), 2012
Figure 8-5: Myriad Genetics - Revenue Breakup by Business Segment (%), 2012
Figure 8-6: Life Technologies - Revenue Breakup by Geography (%), 2012
Figure 8-7: Life Technologies - Revenue Breakup by Business Segment (%), 2012
Figure 8-8: Sequenom - Revenue Breakup by Business Segment (%), 2012
Figure 8-9: Transgenomic - Revenue Breakup by Geography (%), 2012
Figure 8-10: Transgenomic - Revenue Breakup by Business Segment (%), 2012
Figure 8-11: Dako - Revenue Breakup by Geography (%), 2011
Figure 8-12: Gen-Probe, Inc. - Revenue Breakup by Geography (%), 2011
Figure 8-13: Gen-Probe, Inc. - Revenue Breakup by Business Segment (%), 2011
Figure 8-14: Quest Diagnostics - Revenue Breakup by Business Segment (%), 2012

List of Tables:

Table 4-1: Key DTC Genetic Testing Companies by Category (2011)
Table 4-2: Key Test Areas Offered in DTC Genetic Testing Segment (2011)
Table 7-1: Listed Pharmacogenomic Biomarkers in FDA Approved Cancer Therapy Labels
Table 8-1: Abbott Laboratories - Key Gene Based Product(s)
Table 8-2: Abbott Laboratories - Financial Performance (Million US$), 2010-2012
Table 8-5: Roche Molecular Diagnostics - Key Gene Based Product(s)
Table 8-6: Roche Holding - Financial Performance (Million CHF), 2010-2012
Table 8-7: Myriad Genetics - Key Gene Based Product(s)
Table 8-8: Myriad Genetics - Financial Performance (Million US$), 2010-2012
Table 8-9: Life Technologies - Key Gene Based Product(s)
Table 8-10: Life Technologies - Financial Performance (Million US$), 2010-2012
Table 8-11: Genomic Health - Key Gene Based Product(s)
Table 8-12: Genomic Health - Financial Performance (Million US$), 2010-2012
Table 8-13: Sequenom - Key Gene Based Product(s)
Table 8-14: Sequenom - Financial Performance (Million US$), 2010-2012
Table 8-15: Transgenomic - Financial Performance (Million US$), 2010-2012
Table 8-16: Dako - Key Gene Based Product(s)
Table 8-17: Dako - Financial Performance (Million DKK), 2009-2011
Table 8-18: Gen-Probe, Inc. - Key Gene Based Product(s)
Table 8-19: Gen-Probe, Inc. - Financial Performance (Million US$), 2009-2011
Table 8-20: Quest Diagnostics - Gene Based Product(s)/Service(s)
Table 8-21: Quest Diagnostics - Key Financials (Million US$), 2010-2012
Table 8-22: Genoptix - Key Gene Based Service(s)
Table 8-23: Genoptix - Financial Performance (Million US$), 2007-2009
Table 8-24: Clarient - Key Gene Based Service(s)
Table 8-25: Clarient - Financial Performance (Million US$), 2007-2009

Read the full report:

Genetic Testing Market Outlook to 2017

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Molecular Diagnostics in Genetic Testing - 2013 Study Analyzes the Size and Growth of the Molecular Diagnostics in Genetic Testing Market
2. New Book Melds Artificial Intelligence and Genetic Engineering to Create a World of Horror
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. Genetic Test Highly Accurate in Differentiating Thymomas From Thymic Carcinoma Tumors
5. AvidBiotics Announces Research Collaboration with Full Spectrum Genetics
6. and Facebook Campaign Launched to Raise Awareness of Fight to Make Genetic Testing for Breast and Other Cancers More Affordable and Accessible
7. Molecular Cytogenetics Market is Expected to Reach USD 1.97 Billion Globally in 2019: Transparency Market Research
8. Genetic Testing Explodes after Supreme Court Patent Decision
9. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
10. Epigenetic and MicroRNA Biomarkers 2013 Market Report
11. Population Genetics Assigns Asymmetric Adaptor Library Construction Patent To New England Biolabs
Post Your Comments:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):